dc.contributor.author |
Hsiao, Kuang-Chih |
|
dc.contributor.author |
Ponsonby, Anne-Louise |
|
dc.contributor.author |
Ashley, Sarah |
|
dc.contributor.author |
Lee, Cassandra Yuen Yan |
|
dc.contributor.author |
Jindal, Lalita |
|
dc.contributor.author |
PPOIT Study Team |
|
dc.contributor.author |
Masters of advanced practice nursing |
|
dc.contributor.author |
Tang, Mimi LK |
|
dc.coverage.spatial |
England |
|
dc.date.accessioned |
2022-06-22T22:16:32Z |
|
dc.date.available |
2022-06-22T22:16:32Z |
|
dc.date.issued |
2022-04-11 |
|
dc.identifier.citation |
(2022). Clinical and Experimental Allergy. |
|
dc.identifier.issn |
0954-7894 |
|
dc.identifier.uri |
https://hdl.handle.net/2292/60108 |
|
dc.description.abstract |
<h4>Introduction</h4>Probiotic and Peanut Oral Immunotherapy (PPOIT) is effective at inducing sustained unresponsiveness (SU) at end-of-treatment and this effect persists up to four years post-treatment, referred to as persistent SU. We sought to evaluate (i) how PPOIT altered peanut-specific humoral immune indices, and (ii) how such longitudinal indices relate to persistent SU.<h4>Methods</h4>Longitudinal serum/plasma levels of whole peanut- and peanut component- (Ara-h1, -h2, -h3, -h8, -h9) specific-IgE (sIgE) and specific-IgG4 (sIgG4) antibodies were measured by ImmunoCAP and salivary peanut-specific-IgA (sIgA) by ELISA in children (n=62) enrolled in the PPOIT-001 randomised trial from baseline (T0) to 4-years post-treatment (T5). Multivariate regression analyses of log-transformed values were used for point-in-time between group comparisons. Generalised estimating equations (GEE) were used for longitudinal comparisons between groups.<h4>Results</h4>PPOIT was associated with changes in sIgE and sIgG4 over time. sIgE levels were significantly reduced post-treatment [T5, PPOIT v.s. Placebo ratio of geometric mean (GM): Ara-h1 0.07, p=0.008; Ara-h2 0.08, p=0.007; Ara-h3 0.15, p=0.021]. sIgG4 levels were significantly increased by end-of-treatment (T1, PPOIT v.s. Placebo ratio of GM: Ara-h1 3.77, p=0.011; Ara-h2 17.97, p<0.001; Ara-h3 10.42, p<0.001) but levels in PPOIT group decreased once treatment was stopped and returned to levels comparable with Placebo group by T5. Similarly, salivary peanut sIgA increased during treatment, as early as 4 months of treatment (PPOIT v.s. Placebo, ratio of GM: 2.04, p=0.014), then reduced post-treatment.<h4>Conclusion</h4>PPOIT was associated with broad reduction in peanut specific humoral responses which may mediate the clinical effects of SU that persists to 4-years post-treatment. |
|
dc.format.medium |
Print-Electronic |
|
dc.language |
eng |
|
dc.publisher |
Wiley |
|
dc.relation.ispartofseries |
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.subject |
PPOIT Study Team |
|
dc.subject |
Masters of advanced practice nursing |
|
dc.subject |
Peanut allergy |
|
dc.subject |
antibody responses |
|
dc.subject |
desensitisation |
|
dc.subject |
oral immunotherapy |
|
dc.subject |
probiotic |
|
dc.subject |
remission |
|
dc.subject |
sustained unresponsiveness |
|
dc.subject |
Complementary and Integrative Health |
|
dc.subject |
Clinical Trials and Supportive Activities |
|
dc.subject |
Clinical Research |
|
dc.subject |
Biotechnology |
|
dc.subject |
Prevention |
|
dc.subject |
6.1 Pharmaceuticals |
|
dc.subject |
1107 Immunology |
|
dc.subject |
1111 Nutrition and Dietetics |
|
dc.subject |
1117 Public Health and Health Services |
|
dc.title |
Longitudinal antibody responses to peanut following probiotic and peanut oral immunotherapy (PPOIT) in children with peanut allergy. |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.1111/cea.14146 |
|
dc.date.updated |
2022-05-12T04:37:54Z |
|
dc.rights.holder |
Copyright: The author |
en |
dc.identifier.pmid |
35403286 (pubmed) |
|
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/35403286 |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Journal Article |
|
pubs.elements-id |
896732 |
|
pubs.org-id |
Medical and Health Sciences |
|
pubs.org-id |
School of Medicine |
|
pubs.org-id |
Paediatrics Child & Youth Hlth |
|
dc.identifier.eissn |
1365-2222 |
|
pubs.record-created-at-source-date |
2022-05-12 |
|
pubs.online-publication-date |
2022-04-29 |
|